LDC enters new industry partnership for the discovery of novel medicines
LDC and Roche will jointly advance innovative drug discovery projects.
The Lead Discovery Center (LDC) and Roche will collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need across several disease areas.
Projects will be sourced from the LDC’s academic partners, including leading universities and institutes from the Max Planck Society and the Helmholtz Association, as well as from Roche’s innovation network. The partners will work together to advance projects from as early as target level up to the identification of a preclinical candidate. Over an initial 3-year period, LDC will act as a translational incubator for Roche and carry out small molecule projects in close collaboration with the scientific inventors and their academic institutions.
“We are delighted to team up with Roche, the world’s largest biotech company,” says Dr Bert Klebl, CEO of the LDC. “We are impressed by their deep expertise across many disease areas and the perfect cultural fit with our team. We are definitely on the same wavelength regarding our approach to early drug discovery and share a mission to transform academic innovation into tangible benefits to patients.”
Upon attainment of a predefined milestone, Roche has option rights to an exclusive license. The terms and conditions of collaboration and licensing will be agreed on a project-by-project basis to ensure a fair balance of investments and potential returns between the partners. Any revenue the LDC may receive from a potential future commercialization will be shared with the academic inventors and collaborating institutions. Roche’s contributions will include research funding and possibly in-kind support required for optimal project progress, such as access to compound libraries.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance